Company intelligence / Profile preview

Dianosic

Strasbourg, Grand Est/Alsace region, Francedianosic.com ↗

Ownership: Private
Development stage: Other

Overview

Dianosic has demonstrated promising preclinical results for its ARIS-R program targeting chronic allergic rhinitis. The CAVI-T balloon device for epistaxis management has been CE-marked and launched commercially in Europe. Initial formulation studies have begun for CNS indications using the nose-to-brain approach.

Therapeutic areas: HematologyPulmonologyNeurology
Modalities: DeviceDrug-eluting polymer scaffoldPolymer-based drug delivery
Industry: Biotech

Drug pipeline

3 assets

DIA02-S

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Collaborates with healthcare professionals and academic researchers; supported by regional innovation networks such as Quest for Health and Biovalley France. No major pharma partnerships disclosed.

Beyond the preview

Go deeper on Dianosic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dianosic.

Explore the full profile